SCHEMBL16554200

SCHEMBL16554200

CC[Si](C)(C)CC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL632284 0.84 FFAR3 (0.41)
SCHEMBL6047432 0.74 AKR1B1 (0.42)
SCHEMBL128808 0.73 FFAR3 (0.44)
SCHEMBL5711158 0.73 FFAR3 (0.44)
SCHEMBL29065871 0.71 FFAR3 (0.41)
SCHEMBL8415864 0.69
SCHEMBL512768 0.67 FFAR3 (0.38)
SCHEMBL30203760 0.67
Propionic Acid SCHEMBL109638 0.66
SCHEMBL26864957 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105517548-B Combination of MEK inhibitors and ERK inhibitors for the treatment of hyperproliferative disorders 豪夫迈·罗氏有限公司 2020-01-21 CN disclosed
US-9532987-B2 Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases GENENTECH, INC. (US) 2017-01-03 US disclosed
EP-3041471-A1 COMBINATION OF A MEK INHIBITOR AND AN ERK INHIBITOR FOR USE IN TREATMENT OF HYPERPROLIFERATIVE DISEASES F. Hoffmann-La Roche AG (CH) 2016-07-13 EP disclosed
CN-105517548-A Combination of MEK inhibitors and ERK inhibitors for the treatment of hyperproliferative disorders HOFFMANN LA ROCHE 2016-04-20 CN disclosed
US-20150111869-A1 USE OF A COMBINATION OF A MEK INHIBITOR AND AN ERK INHIBITOR FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES GENENTECH, INC. (US) 2015-04-23 US disclosed
WO-2015032840-A1 COMBINATION OF A MEK INHIBITOR AND AN ERK INHIBITOR FOR USE IN TREATMENT OF HYPERPROLIFERATIVE DISEASES F. HOFFMANN-LA ROCHE AG (CH) 2015-03-12 WO disclosed